ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : antibody subclass
Australian State/Territory : NSW
Clear All
Filter by Field of Research
Cancer Therapy (excl. Chemotherapy and Radiation Therapy) (2)
Haematology (2)
Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies) (1)
Biological Mathematics (1)
Clinical Sciences not elsewhere classified (1)
Epidemiology (1)
Immunology (1)
Infectious Diseases (1)
Molecular Medicine (1)
Molecular Targets (1)
Oncology and Carcinogenesis (1)
Solid Tumours (1)
Stochastic Analysis and Modelling (1)
Tumour Immunology (1)
Filter by Socio-Economic Objective
Cancer and Related Disorders (1)
Immune System and Allergy (1)
Preventive Medicine (1)
Filter by Funding Provider
National Health and Medical Research Council (10)
Australian Research Council (1)
Filter by Status
Closed (11)
Filter by Scheme
NHMRC Project Grants (4)
Project Grants (4)
Development Grants (2)
Discovery Projects (1)
Filter by Country
Australia (9)
Filter by Australian State/Territory
NSW (9)
ACT (4)
VIC (4)
NT (1)
  • Researchers (0)
  • Funded Activities (11)
  • Organisations (4)
  • Funded Activity

    Heparin Induced Thrombocytopenia (HIT): Further Characterization Of Disease Mechanism Will Improve Patient Treatment

    Funder
    National Health and Medical Research Council
    Funding Amount
    $456,484.00
    Summary
    Thrombus formation occurs as a side effect of heparin treatment in many patients. This condition is called Heparin Induced Thrombocytopenia (HIT). The clots may be stabilised by secretions from cells called neutrophils. In this project we will study this possibility using a mouse model of HIT and will explore therapeutic approaches to inhibit clot stabilisation.
    More information
    Funded Activity

    Humanisation And Pre-clinical Validation Of A Therapeutic Anti-cancer Antibody

    Funder
    National Health and Medical Research Council
    Funding Amount
    $699,136.00
    Summary
    This grant will develop a novel antibody against a protease expressed on cancer cells. Preclinical studies, and antibody humanisation, will be performed. This project will also provide vital information on optimal therapeutic approaches with the antibody that can be ultimately taken into human trials.
    More information
    Funded Activity

    Signalling Networks As Targets For Antibody Therapy In Glioma.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $526,683.00
    Summary
    Antibodies are a major component of the bodies immune system that bind (i.e. stick) to foreign substances such as viruses. Once bound, these antibodies can activate other parts of the immune system, which help destroy the foreign substance. Analogous to the situation above, a number of institutions are testing antibodies that bind to cancer cells, in order to determine if they are able to destroy these cells. It is also possible to generate antibodies that bind to receptors on the surface of can .... Antibodies are a major component of the bodies immune system that bind (i.e. stick) to foreign substances such as viruses. Once bound, these antibodies can activate other parts of the immune system, which help destroy the foreign substance. Analogous to the situation above, a number of institutions are testing antibodies that bind to cancer cells, in order to determine if they are able to destroy these cells. It is also possible to generate antibodies that bind to receptors on the surface of cancer cells and block their function. If you target a receptor critical to the growth or survival of a cancer cell in this way, then swtiching-off this signal may inhibit tumor growth. In this proposal we plan to test a panel antibodies that recognize receptors important to the growth of brain cancer. Two of these antibodies have been generated and the other two will be made as part of this proposal. A key aspect of this proposal will be testing these antibodies in combination to determine how many receptors need to be targeted in order to get complete tumor regressions in animal models. Overall this work will help us identify new therapeutic strategies for the treatment of brain cancer. Finally, we will also analyze the way different receptors interact together in brain cancer cells.
    Read more Read less
    More information
    Funded Activity

    Cancer Cachexia Therapeutics

    Funder
    National Health and Medical Research Council
    Funding Amount
    $626,680.00
    Summary
    We have discovered a single tumour factor which causes cancer cachexia, a wasting condition that is one of the worst complications of malignancy, for which there is no current effective treatment. We have developed antibodies which effectively block this condition in preclinical models and have produced human/humanised version of this. This application is to characterise these human antibodies to allow us proceed to clinical trials.
    More information
    Funded Activity

    Alpha Particle Therapy Of Solid Tumours

    Funder
    National Health and Medical Research Council
    Funding Amount
    $715,005.00
    Summary
    Alpha-particles linked to recombinant antibodies targeting tumour cells have potential to effectively treat tumours while minimising normal tissue side effects. We will explore a novel alpha-particle therapy approach to solid tumours, by delivering 225Ac directly into tumour cells, or into cells that support the tumour (microenvironment). This approach will hopefully result in development of a new approach to treatment of cancers that are resistant to conventional therapies.
    More information
    Funded Activity

    Heparin-induced Thrombocytopenia And Thrombosis: Better Understanding Of Pathogenesis And Improving Diagnosis And Treatment

    Funder
    National Health and Medical Research Council
    Funding Amount
    $653,137.00
    Summary
    Heparin, a widely used drug, can cause an adverse effect which results in a fall of the platelet count and the development of serious thrombosis. This drug complication is mediated by an immune mechanism. This proposal aims to provide a better understanding of the disease mechanism. It also aims to develop a new test that will improve the diagnosis, and to produce a novel drug that will effectively suppress the immune reaction and improve the treatment.
    More information
    Funded Activity

    Drug-induced Immune Thrombocytopenia: Understanding The Disease Mechanisms Is The Key To Better Treatment

    Funder
    National Health and Medical Research Council
    Funding Amount
    $509,550.00
    Summary
    Many very commonly used medications cause an allergic reaction in a small number of patients that receive them. The allergic reaction results in platelets being destroyed and puts the patients at risk of bleeding. The patient recovers slowly if the drug is stopped but there is no other treatment and no way to reverse the effect quickly if the patient starts to bleed. This project will try to understand the mechanism of the condition and test a potential treatment.
    More information
    Funded Activity

    ADAM Metalloprotease Inhibition For Treatment Of Colorectal Cancer

    Funder
    National Health and Medical Research Council
    Funding Amount
    $770,925.00
    Summary
    Colorectal cancer (CRC) causes over 4000 deaths/year, typically from developing drug resistance and spreading to other organs (metastasis). These processes involve tumour cells called cancer stem cells (CSCs), which rely on specific cell surface proteins for survival and function. We are developing antibodies against one of these type of proteins, to test in mouse models of CRC. These already show promise in targeting CSCs and inhibiting drug-resistance and metastasis in mice.
    More information
    Funded Activity

    A NOVEL MOUSE MODEL TO INVESTIGATE THE MECHANISMS OF VIRUS-INDUCED ARTHRITIS

    Funder
    National Health and Medical Research Council
    Funding Amount
    $336,000.00
    Summary
    We have developed a novel animal model by which to study arthritic disease caused by insect-transmitted viruses known as arboviruses. The existence of this model and novel reagents provides an excellent opportunity to further explore the basic mechanisms of infectious disease in a complete functioning animal, rather than specific cultured cells. The study will use modern approaches in molecular and cellular biology to achieve this goal. The production by our immune systems of soluble mediators ( .... We have developed a novel animal model by which to study arthritic disease caused by insect-transmitted viruses known as arboviruses. The existence of this model and novel reagents provides an excellent opportunity to further explore the basic mechanisms of infectious disease in a complete functioning animal, rather than specific cultured cells. The study will use modern approaches in molecular and cellular biology to achieve this goal. The production by our immune systems of soluble mediators (cytokines-chemokines) and antibodies is an overwhelming positive aspect of our physiological response to infection by microbes. Protection from disease by these immune compounds can happen naturally, or the body's ability to produce these factors can be exploited to our benefit via the administration of vaccines. However, these factors can also be detrimental to the host contributing to severe disease. For instance, work performed almost 40 years ago showed for the first time that under particular conditions, antibodies against viruses can enhance infection, instead of inhibiting infection as normally seen. In the intervening years work by scientists all over the world has associated antibody-dependent enhancement (ADE) of infection to many types of viruses; ADE is even thought to be a risk factor to serious disease with dengue virus, and has been shown in vitro for the AIDS virus and Ebola virus. We have recently discovered a molecular mechanism which explains how antibody enhances viral infection in vitro. In studies on immune cells infected with Ross River Virus (RRV) we found that infection helped by antibody resulted in the specific disruption to the production of cellular chemicals which are toxic to viruses. Are these mechanisms of antibody-enhanced infection also found in animals? Will such mode of infection cause enhanced disease and tissue pathology (arthritis) in animals?
    Read more Read less
    More information
    Funded Activity

    Discovery Projects - Grant ID: DP110104429

    Funder
    Australian Research Council
    Funding Amount
    $340,000.00
    Summary
    Real-time analysis of tumour-infiltrating T cells using novel analytical tools. By dynamic visualization of immune cells within intact tumours, we have shown that active screening for target cells optimises their anti-tumour effect. This project will develop novel mathematical/analytical tools to unravel the basic strategies that enable immune cells to position themselves at the right location at the right time.
    More information

    Showing 1-10 of 11 Funded Activites

    • 1
    • 2
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback